News & Analysis as of

Attorney General Drug Pricing

Skadden, Arps, Slate, Meagher & Flom LLP

Skadden's 2020 Insights

Despite political and economic uncertainties, markets and deal activity were resilient in 2019, and strong fundamentals remain in place heading into 2020. Companies continue to face a challenging litigation and enforcement...more

McGuireWoods Consulting

Next Week in Congress

House and Senate Return to Washington - Both the House and the Senate return to Washington next week. Throughout the week, the appropriations and authorizing committees will continue to hear from department and agency...more

Blank Rome LLP

States Pass Fewer Drug Manufacturer Pricing Disclosure Laws in 2018

Blank Rome LLP on

Merle M. DeLancey Jr. While the introduction of state legislation that would require drug manufacturers to disclose pricing and other information did not slow down in 2018, the number of bills that were made law did slow...more

Cozen O'Connor

The State AG Report Weekly Update February 2019 #3

Cozen O'Connor on

2019 AG Election- Democrat Jennifer Riley-Collins Announces Intention to Run for Mississippi AG- Jennifer Riley-Collins, a Democrat, announced her intention to run for Mississippi AG in 2019. ...more

Smart & Biggar

Federal Court finds PMPRB unreasonable in finding Galderma patent 'pertains to' medicine in DIFFERIN

Smart & Biggar on

In a November 9, 2017 decision, Justice Phelan of the Federal Court found that the Patented Medicine Prices Review Board Panel (Board) was unreasonable in its assessment that a patent ‘pertained’ to Galderma Canada’s DIFFERIN...more

Patterson Belknap Webb & Tyler LLP

DOJ and Stage AG Investigations Into Generic Pricing Lead to Suits Against Manufacturers and Employees

As we have previously reported, (click, here, here, here, and here to read more), generic drug manufacturers have recently come under intense scrutiny from state and federal regulators for their price hikes. Last week, the...more

Foley & Lardner LLP

Three Dozen States Sue Makers of Opioid Addiction Treatment Medications for Antitrust

Foley & Lardner LLP on

With opioid abuse continuing to dominate national headlines, manufacturers of opioid overdose medications are facing intense scrutiny over pricing practices that threaten (or those perceived as threatening) public...more

BakerHostetler

Vermont to Require Drug Transparency

BakerHostetler on

Vermont recently became the first state to require drug manufacturers to provide justification for price increases. Under the new law, data on the cost of the drug will come from the state Medicaid program. The Department of...more

Cooley LLP

Blog: States Taking The Lead On Drug Pricing Policy; Will Congress Enter The Fray?

Cooley LLP on

Last week, Vermont adopted the first state law that requires drug companies registering the highest hike in prices to justify the rationale for the increase. Vermont policymakers are not alone pursuing laws that address...more

Mintz - Health Care Viewpoints

State Pharmaceutical Pricing Disclosure Laws: Old Story, New Refrain

As a veteran of the AWP litigation era, I am struck by the recent state efforts to legislate transparency into pharmaceutical pricing. Multiple states have introduced bills that would require pharmaceutical manufacturers to...more

10 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide